Updated:
Rosetta Capital Limited
Rosetta Capital Limited is a London venture firm backing early-stage healthcare and life sciences companies in Europe since 2002.
Rosetta Capital Limited
Rosetta Capital was founded in 2002 in London, where it remains headquartered. The partnership — including John Scott and Andrew Muir — invests exclusively in European healthcare and life sciences, a sector mandate unchanged since inception. The firm's capital comes from institutional investors, family offices, and high-net-worth individuals, though its ownership structure is not publicly detailed. The strategy focuses on seed and Series A rounds, deploying ticket sizes between £500,000 and £3 million per deal. Sectors covered include biotech, medical devices, diagnostics, and digital health. Portfolio companies have included Proximagen (neuroscience, acquired by Upsher-Smith in 2012), Summit Therapeutics (antibiotics, listed on NASDAQ), and Circassia (respiratory, listed on LSE). The firm typically leads or co-invests in syndicates with other European specialist healthcare VCs. With around five professionals operating from a single London office, Rosetta Capital maintains a concentrated portfolio of active companies, typically fewer than 15 at any time. The firm reports exits across its funds, including IPOs and trade sales, but does not publish aggregate AUM or deployment figures. No public event in the last 24 months was identified beyond typical fund-follow-on activity. What sets Rosetta Capital apart from generalist European VCs is its unyielding sector focus: it will not invest outside healthcare or outside Europe. The mandate has remained identical for two decades, and the small partnership structure means all partners sit on boards of portfolio companies. This narrow specialization allows the firm to lean heavily on domain expertise rather than a diversified fund strategy.
General information
Firm type
Asset Manager
Year founded
2002
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Principals
John Scott
Partner
Andrew Muir
Partner
Sector focus
Frequently asked questions
Who leads investment decisions at Rosetta Capital?
John Scott and Andrew Muir are the publicly named partners overseeing investment decisions. The firm operates with a lean team of around five investment professionals, all based in London. Investment decisions are made collaboratively by the partnership, with each partner typically sitting on the board of portfolio companies (per public record).
What investment stages does Rosetta Capital target?
Rosetta Capital focuses on seed and Series A funding rounds in European healthcare and life sciences companies. Tickets typically range from £500,000 to £3 million per deal. The firm generally leads or co-invests in syndicates with other specialist European VCs.
What is the firm's geographic focus?
Rosetta Capital invests exclusively in Europe, with a particular emphasis on the UK, Ireland, and Western Europe. It does not invest outside the continent. This geographic constraint has been consistent since the firm's founding in 2002.
Is Rosetta Capital a single family office or a venture firm?
Rosetta Capital is structured as a venture capital firm, not a family office. It raises capital from institutional investors and family offices, but its ownership and management are based on a partnership model. The firm does not disclose whether its partners invest personal capital alongside institutional LPs.
Which sectors does Rosetta Capital explicitly avoid?
Rosetta Capital explicitly avoids any sectors outside healthcare and life sciences. It does not invest in technology, software, fintech, clean energy, or any other non-healthcare vertical. The firm's mandate also excludes investments outside Europe.
Does Rosetta Capital participate in fund commitments or only direct deals?
Rosetta Capital makes only direct equity investments in early-stage companies. It does not commit to other funds or operate as a fund-of-funds. All deployments go directly into portfolio company equity, typically with board representation.
How does Rosetta Capital source proprietary deal flow?
The firm sources deals through a network of European university technology transfer offices, hospitals, and existing portfolio company referrals. Its long tenure and sector specialization provide repeat deal flow from institutional co-investors. The small team reviews hundreds of opportunities annually to select three to five new investments per year.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: